| Literature DB >> 29323197 |
Juan P Caballero-Romeu1, Juan A Galán-Llopis2, Federico Soria3, Esther Morcillo-Martín3, Pablo Caballero-Pérez4, Julia E De La Cruz-Conty3, Jesús Romero-Maroto5.
Abstract
Miniaturization of ureteroscopy materials is intended to decrease tissue damage. However, tissue hypoxia and the gross and microscopic effects on tissue have not been adequately assessed. We compared the gross and microscopic effects of micro-ureteroscopy (m-URS) and conventional ureteroscopy (URS) on the urinary tract. We employed 14 pigs of the Large White race. URS was performed in one of the ureters with an 8/9.8 F ureteroscope, while a 4.85 F m-URS sheath was used in the contralateral ureter. Gross assessment of ureteral wall damage and ureteral orifice damage was performed. For microscopic assessment hematoxylin-eosin staining and immunohistochemistry for detection of tissue hypoxia were conducted. Regarding the macroscopic assessment of ureteral damage, substantial and significant differences were recorded using URS (C = 0.8), but not with m-URS. Microscopic assessment after staining with hematoxylin-eosin revealed greater epithelial desquamation in the URS group (p < 0.05). Pimonidazole staining revealed greater hypoxia in the epithelial cells than in the remainder of the ureteral layers. We conclude that m-URS causes less damage to the ureteral orifice than URS. Histopathological findings show m-URS reduces ureteral epithelial damage compared with conventional ureteroscopy. Both URS and m-URS cause cellular hypoxia.Entities:
Mesh:
Year: 2018 PMID: 29323197 PMCID: PMC5765032 DOI: 10.1038/s41598-017-18885-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1A longitudinal view of the m-URS ureteroscope and 4.85 F sheath is shown at the top. The tips of both instruments are shown at the bottom.
Macroscopic evaluation of tissue damage.
| Scale n (%) | L | Effect size | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | Wil.+ | C | 95% CI | ||||
|
| ||||||||||
| Score | Baseline | URS | 13 (100) | 0 | 0 | 0 | 1 | 66.0** | 0.8 | (0.5; 1.0) |
| m-URS | 13 (100) | 0 | 0 | 0 | 2 | 3.0 | 0.2 | (0.0; 0.3) | ||
| End | URS | 2 (15.4) | 9 (69.2) | 2 (15.4) | 0 | 5 | 0.0** | −0.7 | (−0.9; −0.4) | |
| m-URS | 11 (84.6) | 2 (15.4) | 6 | 0.0** | −0.7 | (−0.9; −0.4) | ||||
|
| ||||||||||
| PULS | Baseline | URS | 13 (100) | 0 | 0 | 0 | 1 | 3.0 | 0.2 | (0.0; 0.3) |
| m-URS | 13 (100) | 0 | 0 | 0 | 2 | 1.0 | 0.1 | (−0.1; 0.2) | ||
| 30 min | URS | 12 (92.3) | 0 | 0 | 1 (7.7) | 3 | 1.0 | 0.1 | (−0.1; 0.2) | |
| m-URS | 12 (92.3) | 1 (7.7) | 0 | 0 | 4 | 1.0 | 0.1 | (−0.1; 0.2) | ||
| End | URS | 12 (92.3) | 1 (7.7) | 0 | 1 (7.7) | 5 | 1.5 | 0.1 | (−0.2; 0.3) | |
| m-URS | 12 (92.3) | 1 (7.7) | 0 | 0 | 6 | 1.5 | 0.1 | (−0.2; 0.3) | ||
Wil.+: Wilcoxon positive range statistic. C. Cliff’s delta. 95% CI: 95% confidence interval for Cliff’s delta. L: Legend, comparison between 1; Final URS vs Baseline URS,
2; Final m-URS vs Baseline mURS,3; 30 minutes URS vs Baseline URS,4; 30 minutes m-URS vs Baseline m-URS,
5; Final URS vs Final m-URS, 6; Final URS-Baseline URS vs Final m-URS – Baseline m-URS *p < 0.05, **p < 0.01.
Figure 2Comparison of the condition of the ureteral orifices after ureteral exploration. The ureteral orifice of a ureter explored with m-URS is shown at left. The ureteral orifice of a ureter explored with URS is shown at right.
Histopathological evaluation (hematoxylin-eosin staining).
| Absent | Focal | Diffuse | Severe | L | Wil.+ | Effect size | |||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | C | 95% CI | ||||
|
| |||||||||
|
| |||||||||
| Prox. u. | URS | 3 (21.4) | 11 (78.6) | 0 | 0 | 1 | 55** | 0.8 | (0.5; 0.9) |
| m-URS | 3 (21.4) | 11 (78.6) | 0 | 0 | 2 | 24.5 | 0.3 | (0.0; 0.6) | |
| Distal u. | URS | 0 | 4 (28.6) | 5 (35.7) | 5 (35.7) | 3 | 0** | −0.5 | (−0.8; −0.1) |
| m-URS | 1 (7.1) | 10 (71.4) | 2 (14.3) | 1 (7.1) | 4 | 0** | −0.5 | (−0.8; −0.1) | |
|
| |||||||||
|
| |||||||||
| Prox. u. | URS | 4 (28.6) | 8 (57.1) | 2 (14.3) | 0 | 1 | 45.5 | 0.2 | (−0.2; 0.6) |
| m-URS | 3 (21.4) | 8 (57.1) | 3 (21.4) | 0 | 2 | 27.5 | 0.0 | (−0.4; 0.4) | |
| Distal u. | URS | 4 (28.6) | 4 (28.6) | 5 (35.7) | 1 (7.1) | 3 | 16.5 | −0.1 | (−0.5; 0.3) |
| m-URS | 3 (21.4) | 8 (57.1) | 3 (21.4) | 0 | 4 | 16.5 | −0.2 | (−0.6; 0.2) | |
|
| |||||||||
| Prox. u. | URS | 5 (35.7) | 6 (42.9) | 3 (21.4) | 1 | 7 | −0.1 | (−0.5; 0.3) | |
| m-URS | 7 (50.0) | 6 (42.9) | 1 (7.1) | 2 | 7 | −0.1 | (−0.5; 0.3) | ||
| Distal u. | URS | 4 (28.6) | 10 (71.4) | 0 | 3 | 3.5 | −0.3 | (−0.6; 0.1) | |
| m-URS | 8 (57.1) | 6 (42.9) | 0 | 4 | 3.5 | 0.0 | (0.4; −0.4) | ||
|
| |||||||||
| Prox. u. | URS | 10 (71.4) | 1 (7.1) | 3 (21.4) | 1 | 40.5 | 0.2 | (−0.2; 0.6) | |
| m-URS | 8 (57.1) | 6 (42.9) | 0 | 2 | 28 | 0.3 | (−0.1; 0.6) | ||
| Distal u. | URS | 5 (35.7) | 8 (57.1) | 1 (7.1) | 3 | 30 | 0.0 | (−0.3; 0.4) | |
| m-URS | 5 (35.7) | 7 (50.0) | 2 (14.3) | 4 | 30 | 0.0 | (0.4; −0.4) | ||
|
| |||||||||
| Prox. u. | URS | 11 (78.6) | 3 (21.4) | 0 | 1 | 6 | 0.2 | (−0.2; 0.5) | |
| m-URS | 12 (85.7) | 2 (14.3) | 0 | 2 | 1.5 | 0.0 | (−0.3; 0.3) | ||
| Distal u. | URS | 9 (64.3) | 4 (28.6) | 1 (7.1) | 3 | 3.5 | −0.2 | (−0.5; 0.1) | |
| m-URS | 12 (85.7) | 2 (14.3) | 0 | 4 | 3.5 | −0.2 | (−0.5; 0.1) | ||
|
| |||||||||
| Prox. u. | URS | 14 (100) | 0 | 1 | 3 | 0.1 | (−0.1; 0.3) | ||
| m-URS | 14 (100) | 0 | 2 | 0 | 0.0 | (0.0; 0.0) | |||
| Distal u. | URS | 12 (85.7) | 2(14.3) | 3 | 0 | −0.1 | (−0.3; 0.1) | ||
| m-URS | 14 (100) | 0 | 4 | 0 | −0.1 | (−0.3; 0.1) | |||
|
| |||||||||
|
| |||||||||
| Prox. u. | URS | 12 (85.7) | 2 (14.3) | 1 | 7.5 | 0.1 | (−0.2; 0.4) | ||
| m-URS | 11 (78.6) | 3 (21.4) | 2 | 9 | 0.1 | (−0.3; 0.4) | |||
| Distal u. | URS | 10 (71.4) | 4 (28.6) | 3 | 10.5 | 0.0 | (−0.3; 0.3) | ||
| m-URS | 10 (71.4) | 4 (28.6) | 4 | 10.5 | −0.1 | (−0.4; 0.3) | |||
Wil.+: Wilcoxon positive range statistic. C. Cliff’s delta. 95% CI: 95% confidence interval for Cliff’s delta. L: Legend, comparison between 1; Distal u. URS vs Prox. u. URS, 2; Distal u. m-URS vs Prox. u. m-URS, 3; Distal u. URS vs Distal u. m-URS,
4; Distal u. URS - Prox. u. Baseline URS vs Distal u. m-URS – Prox. u. m-URS, *p < 0.05, **p < 0.01.
Figure 3Ureter. (A) Intact epithelium (Lesion grade 0). (B) Loss of epithelium affecting less than half of the mucosa; focal loss (Lesion grade 1). (C) Intact epithelium of the ureter; lamina propria showing fibrosis extending towards the muscle layer (arrows). (D) In total, denuded mucosa; total loss of epithelium (Lesion grade 3). *Indicates moderate connective tissue edema of the lamina propria.
Figure 4Ureter. (A) Loss of epithelium affecting less than half of the mucosa; focal loss (Lesion grade 1). The arrow indicates diffuse inflammatory infiltrate (B and C) Focal inflammatory infiltrates in the lamina propria.
Evaluation of lamina propria damage according to procedure.
| Number of cases of damage | L | Wil.+ | Effect size | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | ||||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | C | 95% CI | ||||
| Prox. u. | URS | 0 | 6 (42.9) | 4 (28.6) | 4 (28.6) | 0 | 0 | 1 | 38.0 | 0.3 | (−0.1; 0.7) |
| m-URS | 1 (7.1) | 5 (35.7) | 3 (21.4) | 5 (35.7) | 0 | 0 | 2 | 32.5 | 0.1 | (−0.3; 0.5) | |
| Distal u. | URS | 0 | 2 (14.3) | 7 (50.0) | 1 (7.1) | 3 (21.4) | 1 (7.1) | 3 | 22.5 | 0.1 | (−0.3; 0.5) |
| m-URS | 1 (7.1) | 3 (21.4) | 5 (35.7) | 5 (35.7) | 0 | 0 | 4 | 37.0 | −0.2 | (−0.6; 0.2) | |
Wil.+: Wilcoxon positive range statistic. C. Cliff’s delta. 95% CI: 95% confidence interval for Cliff’s delta. L: Legend, comparison between 1; Distal ureter URS vs Proximal ureter URS, 2; Distal ureter m-URS vs Proximal ureter m-URS, 3; Distal ureter URS vs Distal ureter m-URS,
4; Distal ureter URS - Proximal ureter. Baseline URS vs Distal ureter m-URS – Distal ureter. m-URS, *p < 0.05, **p < 0.01.
Immunohistochemical evaluation.
| Absent | Present in few | Present in most | L | Wil.+ | Effect size | 95% CI | ||
|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | C | |||||
|
| ||||||||
|
| ||||||||
| Prox. u. | URS | 2 (14.3) | 5 (35.7) | 7 (50.0) | 1 | 0 | −0.1 | (−0.5; 0.3) |
| m-URS | 2 (14.3) | 6 (42.9) | 6 (42.9) | 2 | 25 | 0.0 | (−0.4; 0.4) | |
| Distal u. | URS | 2 (18.2) | 5 (45.5) | 4 (36.4) | 3 | 3 | 0.1 | (−0.3; 0.5) |
| m-URS | 1 (7.1) | 7 (50.0) | 6 (42.9) | 4 | 6 | 0.2 | (−0.2; 0.6) | |
|
| ||||||||
| Prox. u. | URS | 5 (35.7) | 3 (21.4) | 6 (42.9) | 1 | 0* | −0.2 | (−0.5; 0.2) |
| m-URS | 6 (42.9) | 4 (28.6) | 4 (28.6) | 2 | 12 | 0.1 | (−0.4; 0.5) | |
| Distal u. | URS | 6 (54.5) | 2 (18.2) | 3 (27.3) | 3 | 10* | 0.2 | (−0.2; 0.5) |
| m-URS | 4 (28.6) | 7 (50.0) | 3 (21.4) | 4 | 10* | 0.4 | (0.0; 0.7) | |
|
| ||||||||
|
| ||||||||
| Prox. u. | URS | 9 (64.3) | 5 (35.7) | 0 | 1 | 12 | 0.2 | (−0.2; 0.5) |
| m-URS | 7 (50.0) | 7 (50.0) | 0 | 2 | 18 | 0.0 | (−0.4; 0.3) | |
| Distal u. | URS | 7 (50.0) | 6 (42.9) | 1 (7.1) | 3 | 6 | −0.1 | (−0.4; 0.3) |
| m-URS | 8 (57.1) | 5 (35.7) | 1 (7.1) | 4 | 3 | −0.2 | (−0.5; 0.3) | |
| Substance | ||||||||
| Prox. u. | URS | 14 (100) | 0 | 0 | 1 | |||
| m-URS | 14 (100) | 0 | 0 | 2 | ||||
| Distal u. | URS | 14 (100) | 0 | 0 | 3 | |||
| m-URS | 14 (100) | 0 | 0 | 4 | ||||
|
| ||||||||
|
| ||||||||
| Prox. u. | URS | 7 (50.0) | 7 (50.0) | 0 | 1 | 4 | 0.0 | (−0.4; 0.4) |
| m-URS | 12 (85.7) | 2 (18.2) | 0 | 2 | 10 | 0.2 | (−0.1; 0.5) | |
| Distal u. | URS | 8 (57.1) | 4 (28.6) | 2 (18.2) | 3 | 5 | 0.0 | (−0.4; 0.4) |
| m-URS | 9 (64.3) | 2 (18.2) | 3 (21.4) | 4 | 2 | 0.2 | (−0.1; 0.5) | |
| Cytoplasm | ||||||||
| Prox. u. | URS | 14 (100) | 0 | 0 | 1 | |||
| m-URS | 14 (100) | 0 | 0 | 2 | ||||
| Distal u. | URS | 14 (100) | 0 | 0 | 3 | |||
| m-URS | 14 (100) | 0 | 0 | 4 | ||||
|
| ||||||||
|
| ||||||||
| Prox. u. | URS | 10 (71.4) | 2 (18.2) | 2 (18.2) | 1 | 7.5 | 0.0 | (−0.3; 0.3) |
| m-URS | 11 (78.6) | 2 (18.2) | 1 (7.1) | 2 | 5 | 0.0 | (−0.3; 0.3) | |
| Distal u. | URS | 10 (71.4) | 2 (18.2) | 2 (18.2) | 3 | 2.5 | −0.1 | (−0.4; 0.3) |
| m-URS | 11 (78.6) | 2 (18.2) | 1 (7.1) | 4 | 7.5 | −0.1 | (−0.4; 0.3) | |
Wil.+: Wilcoxon positive range statistic. C. Cliff’s delta. 95% CI: 95% confidence interval for Cliff’s delta. L: Legend, comparison between 1; Distal u. URS vs Prox. u. URS, 2; Distal u. m-URS vs Prox. u. m-URS, 3; Distal u. URS vs Distal u. m-URS,
4; Distal u. URS - Prox. u. Baseline URS vs Distal u. m-URS – Prox. u. m-URS, *p < 0.05, **p < 0.01.
Figure 5Ureter. (A) Positive pimonidazole immunohistochemical staining at the epithelial level (nucleus and cytoplasm), in cells of the lamina propria and nuclei of muscle cells. (B) Negative pimonidazole immunohistochemical staining. (C) Pimonidazole immunohistochemical staining at the epithelial level (positive nucleus and negative cytoplasm). (D) Positive pimonidazole immunohistochemical staining at the epithelial level (nucleus and cytoplasm), negative in the lamina propria. (E) Positive pimonidazole immunohistochemical staining at the epithelial level (nucleus and cytoplasm), negative in the lamina propria. See flat epithelium (dilated ureter).
Figure 6Ureter. (A) Positive pimonidazole immunohistochemical staining of the almost entirely lost epithelium (nucleus and cytoplasm) and in some cells of the lamina propria. (B) Positive pimonidazole immunohistochemical staining at the epithelial level (nucleus and cytoplasm), in cells of the lamina propria and nuclei of muscle cells. (C) Positive pimonidazole immunohistochemical staining at the epithelial level (nucleus and cytoplasm of some cells) and in nuclei of muscle cells. (D) Amplification of image C. (E) Positive pimonidazole immunohistochemical staining of some epithelial cells, negative in the lamina propria. Note the difference between positive and negative cells. (F) Amplification of image (E) Positive and negative cells in the same sample. Positive nucleus and positive and negative cytoplasm.